Radiotherapy Clinical Trial
— T-QAPOfficial title:
T-QAP: radioTherapy eQuicie Adolescent - Pediatrics
This study proposes a horse-assisted therapy (HAT) approach to accompany children and young adults undergoing irradiation in the ICANS Radiotherapy Department. The aim of this new approach is to improve quality of life and reduce anxiety in children and adolescents treated with radiotherapy. The impact of equine-assisted therapy on quality of life and anxiety disorders will be described prospectively between the start and end of irradiation in children and parents who agree to inclusion.
Status | Not yet recruiting |
Enrollment | 22 |
Est. completion date | December 15, 2025 |
Est. primary completion date | December 15, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 17 Years |
Eligibility | Inclusion Criteria: - Children aged 8 to <18 years. - With an indication for radiotherapy for cancer (of any type) - Patients hospitalized and/or managed on an ambulatory basis - WHO = 2 - Child and parents (or accompanying adults) who speak and understand French - Free, express and informed consent of the adult patient OR of those exercising parental authority for minor patients - Child with social security coverage Exclusion Criteria: - Children afraid of horses and stables - Contraindication to the practice of equine-assisted therapy (allergy to horses or dust, children with asthma attacks triggered by dust/animal hair ...) - Patient on stretcher - Children or parents (or carers) with significant cognitive impairment, making self-assessment or hetero-assessment impossible even with assistance - Unavailability or lack of interest in participating in equine-assisted therapy sessions |
Country | Name | City | State |
---|---|---|---|
France | Institut de Cancerologie Strasbourg Europe | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
Institut de cancérologie Strasbourg Europe |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evolution of quality of life between the beginning and the end of horse-assisted therapy (HAT) in children (self-questionnaire) treated with radiotherapy | The questionnaire used to assess quality of life will be completed by the child.
Two versions of the VSP-A questionnaire exist, depending on the child's age (versions < 10 years and 10-17 years). Results can be compared with reference values for the general population. |
before radiotherapy, halfway through the HAT sessions (at 5 weeks), at the end of the HAT sessions (at 10 weeks) and one month after the end of the HAT sessions | |
Secondary | Improving children's quality of life between the start and end of irradiation (hetero-questionnaire) by HAT | Parents (or carers) will complete a questionnaire to assess their child's quality of life. | before radiotherapy, halfway through the HAT sessions (at 5 weeks), at the end of the HAT sessions (at 10 weeks) and one month after the end of the HAT sessions | |
Secondary | Decrease anxiety disorders between the beginning - child version and end of irradiation in children (self-questionnaire) with HAT | The questionnaire used to assess anxiety will be completed by the child (SCARED child version) | before radiotherapy, halfway through HAT sessions (at 5 weeks), at the end of HAT sessions (at 10 weeks) and one month after the end of HAT sessions | |
Secondary | Decrease anxiety disorders between the beginning - parents' version and end of irradiation in children (self-questionnaire) with HAT | Parents (or carers) will also complete a questionnaire to assess their child's anxiety (SCARED parents' version) | before radiotherapy, halfway through HAT sessions (at 5 weeks), at the end of HAT sessions (at 10 weeks) and one month after the end of HAT sessions | |
Secondary | Assessing the acute side effects of radiotherapy at the start and end of irradiation | Evaluation of acute toxicities induced by radiotherapy CTCAE version 5 scale | at the start and end of radiotherapy sessions (from 3 to 7 weeks) | |
Secondary | Study the relevance of the various equestrian activities proposed as a strategy for improving care through the horse | Study the link between the various equestrian activities and the quality of life reported by children. Dashboard to track the duration of each activity carried out per child and per session, completed by the equestrian. | At every HAT sessions (up to 10 weeks) | |
Secondary | Evaluate participant's expectations and satisfaction with their care | questionnaire | at the beginning and end of HAT sessions (up to 10 weeks) | |
Secondary | Assess the medical electroradiology technician's (MERT's) impression of the child's well-being during irradiation | MERT's assessment of the impact of HAT on the child's well-being, based on a retrospective questionnaire for the previous week. | every week during radiotherapy (from 3 to 7 weeks) | |
Secondary | Assessing the impact of HAT on the child during irradiation according to the MERT | at each radiotherapy session (from 3 to 7 weeks) | ||
Secondary | Evaluate the rider's impression of the child's well-being of the child during HAT sessions | Equestrian appreciation of the impact of HAT on the child's well-being during HAT sessions using questionnaires | at the end of the first session and at the end of the last session of HAT (up to 10 weeks) | |
Secondary | Assessing the impact of an alternative activity on parents' satisfaction with care | Open questionnaire at the end of HAT to be completed by parents | at the end of the HAT sessions (at 10 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03212742 -
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06190782 -
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
|
Phase 3 | |
Recruiting |
NCT06120127 -
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
|
Phase 2 | |
Recruiting |
NCT05176002 -
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05909137 -
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
|
||
Recruiting |
NCT02661152 -
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.
|
Phase 3 | |
Withdrawn |
NCT02542137 -
Abscopal Effect for Metastatic Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
Completed |
NCT01168479 -
FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT03658343 -
T2* MRI Analysis for Sarcoma
|
N/A | |
Completed |
NCT03280719 -
Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions
|
N/A | |
Recruiting |
NCT05514327 -
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
|
N/A | |
Recruiting |
NCT05515796 -
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
|
Phase 2 | |
Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
Recruiting |
NCT03370926 -
FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
|
N/A | |
Active, not recruiting |
NCT03870919 -
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
|
N/A | |
Active, not recruiting |
NCT02428049 -
Radiation Pneumonitis After SBRT for NSCLC
|
||
Recruiting |
NCT04923620 -
Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
|
||
Active, not recruiting |
NCT05371795 -
Comparison on Radiotherapy Permanent Skin Marking With Lancets and an Electric Marking Device
|
N/A | |
Recruiting |
NCT03210428 -
Quantitative MR Imaging in Locally Advanced Cervical Cancer
|